{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122821","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.922410+00:00","generated_at":"2026-05-21T00:00:58.577122+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial","bullets":["70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.","Safety profile unchanged in follow-up; majority of adverse events resolved by week 52.","BLA submission for veligrotug in TED on track for H2 2025; company preparing for potential U.S. launch in 2026.","Veligrotug received Breakthrough Therapy Designation, supporting Priority Review eligibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122821","json":"https://secwatch.observer/filing/0001193125-25-122821.json","markdown":"https://secwatch.observer/filing/0001193125-25-122821.md","text":"https://secwatch.observer/filing/0001193125-25-122821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/0001193125-25-122821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/d938560d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:00:58.577122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}